Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.
Study Type
OBSERVATIONAL
Enrollment
133
Université de Lorraine, CHRU Nancy and APEMAC
Vandœuvre-lès-Nancy, Lorraine, France
Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients
Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the age of giv free patients with Pneumocystis jirovecci pneumonia
age in years
Time frame: Between the first january 2004 and the 31th december 2021
To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia
BMI in kg/m2 (quanti
Time frame: Between the first january 2004 and the 31th december 2021
To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia
Charlson comorbidity index as a quantitative variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia
Comorbidities as categorial variables
Time frame: Between the first january 2004 and the 31th december 2021
To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia
Medications as categorial variables
Time frame: Between the first january 2004 and the 31th december 2021
To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients
Type of first symptoms as categorial variables
Time frame: Between the first january 2004 and the 31th december 2021
To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients
Date of first symptoms as quantitative variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia
pO2 (in mmHg)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia
PCR (mg/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia
WBC (G/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia
Creatinine (µmol/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia
LDH (MUI/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia
albumin (g/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia
immunoglobulin (g/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia
lymphocytes (G/L)
Time frame: Between the first january 2004 and the 31th december 2021
To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia
PCR pneumocystis in ct
Time frame: Between the first january 2004 and the 31th december 2021
To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia
Immunofluorescence as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia
Specific coloration as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia
Nasal canula as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia
High flow oxygenation as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia
Mechanical ventilation as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia
Duration in days
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia
cotrimoxazole as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia
atovaquone as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia
pentamidine as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia
steroïd as a categorial variable
Time frame: Between the first january 2004 and the 31th december 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.